Financial News
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
May 05, 2023 at 10:49 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ: TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial ↗
Today 17:02 EDT
What RBB Bancorp (RBB) Said on Its Q3 Earnings Call ↗
Today 16:03 EDT
Equifax Q3 Earnings Call Highlights ↗
Today 16:03 EDT
Home Bancorp Q3 Earnings Call Highlights ↗
Today 16:03 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
